Skip to content
星期一, 8 八月, 2022
Latest:
  • 智慧財產
  • 媒體新聞
  • 獲獎實績
  • 學術發表
長弘生物科技股份有限公司

長弘生物科技股份有限公司

研發抗癌藥物的明日之星

  • 關於長弘
  • 創辦人的話
  • 產品研發
  • 智慧財產
  • 最新消息
  • 聯絡我們
  • EN

Archives

Local delivery therapy of Cerebraca® Wafer being highlighted in the natural review

Read more

Case report – Cerebraca® Wafer implantation combined with CIK therapy for the treatment of recurrent Glioblastoma revealed superior clinical outcome (overall survival extended for more than 24 months).

Read more

Case report – Cerebraca® Wafer implantation for the treatment of un-resectable cervical spine Glioblastoma resulted in the tumor regression.

Read more

Outstanding clinical outcomes were published in various journals. We have listed as follows:

Read more

EN NEWS

  • Local delivery therapy of Cerebraca® Wafer being highlighted in the natural review
    2022-06-27 , EN_News
  • Case report – Cerebraca® Wafer implantation combined with CIK therapy for the treatment of recurrent Glioblastoma revealed superior clinical outcome (overall survival extended for more than 24 months).
    2022-06-27 , EN_News
  • Case report – Cerebraca® Wafer implantation for the treatment of un-resectable cervical spine Glioblastoma resulted in the tumor regression.
    2022-06-27 , EN_News
  • Outstanding clinical outcomes were published in various journals. We have listed as follows:
    2022-06-27 , EN_News
Copyright © 2022 長弘生物科技股份有限公司. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.